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Abstract
Background: Since 2013 StopTB Italia Onlus supports the Senegalese National Tuberculosis Programme by improving
diagnostic capability with technological interventions, ameliorating educational programs for health care personnel,
rising awareness among civil society and providing economical support for patients during treatment. The purpose of
our study was to assess the preliminary results of an interventional cooperation project in a peripheral health care
facility in Senegal.
Methods: An observational, retrospective, pre-post study was conducted to compare Tuberculosis (TB) retention in
care and outcome between a one-year period before and a four-year period after.
Results: Overall, 239 patients with active TB were included, 196 (82%) of whom after the starting of the collaboration
project. At diagnosis 35/43(81.4%) vs 151/196 (77%) patients were smear sputum positive before and after the
beginning of the project, respectively.
At 2 months follow up 23/35 (65.7%) patients in 2012 vs. 139/151 (92%) patients in 2013–2016 had negative control
AFB stain (p = 0.249), 4/35 (11.4%) vs 12/151 (8%) patients remained AFB stain positive (p = 0.17), 7/35 (20%) vs 0/151
died before the 2 months follow up (p < 0.0001). TB treatment outcome was more frequently favourable after the
beginning of cooperation 29/43 (67.4%) vs. 176/196 (89.8%) patients, (p < 0.0001). Patients’ mortality during treatment
decreased from 8/43 (18.6%) in 2012 to 11/196 (5.6%) patients in the following years (p = 0.009).
Conclusion: The implementation of diagnostic procedures, if integrated in a socio-economical intervention, impacts
favourably on TB retention in care and treatment outcomes.
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Background
Ending the global tuberculosis (TB) epidemic by the year
2035 is one of the most ambitious goals of World Health
Organization (WHO). The WHO strategy is based on
three major pillars: improving TB prevention and care,
supporting bold policies and enhancing research and
innovation [1]. In 2016, 1.6 million people died from
Mycobacterium tuberculosis (MTB) [2]. The prompt
diagnosis of new cases is necessary to reduce TB burden,
especially in low-income countries (LIC) where incidence
is elevated and undiagnosed cases remain an oppressive
issue [1, 2]. For example, in 2016, the total number of TB
cases notified in the WHO African-region was above one
million, accounting for an incidence of 254 cases every
100,000 inhabitants (range 227–284) [2]. In Senegal,
where this project was conducted, the incidence of active
TB seems to have increased since the last 15 years; in fact,
in 2016 the incidence reached 140 (range 95–193) cases
every 100,000 inhabitants (range 100–198) [2–4]. How-
ever, jeopardized case-finding and case-notification do not
allow a precise estimation of the real TB burden in the
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whole country, which are merely based on case notifica-
tions and expert opinions [2, 4]. In addition, the gross do-
mestic product of Senegal has been decreasing and more
than 68% of the population in the Fatick region is cur-
rently living under the threshold of poverty, actively con-
curring to exacerbate the disease burden [5, 6]. The
Senegalese “National Tuberculosis Programme” (NTP), in
accordance with WHO guidelines, points to end the TB
epidemic and suggests an appropriate treatment of all pa-
tients with clinical and/or microbiological and/or radio-
logical signs of TB [4]. Since 2013 StopTB Italia Onlus
sustains the Senegalese NTP, along with the economic aid
of “Fondazione Monzino” and in collaboration with “Yun-
gar per la pace” [7], a NGO that supports alphabetization
of women in Senegal. The cooperation project aims to
ameliorate TB treatment as well as to address the social/
economic determinants of the illness. The policy consists
in improving diagnostic capability with technological in-
terventions, ameliorating educational programs for health
care personnel, rising awareness among civil society and
providing economical support for patients during treat-
ment. The purpose of our study was to assess the results
of an interventional cooperation project aimed at increas-
ing illness awareness, ameliorate treatment outcome and
providing patients’ economic support in a peripheral
health care facility in Senegal where no data were previ-
ously available.
Methods
Location of the project
The present research was conducted at the Health
Centre of Diofior (HCD), a tertiary level health care
centre, serving the Fimela district in the Fatick region of
Senegal. The HCD serves an area of 1115 km2 and an
estimated population of 80,599 inhabitants (population
density: 72 inhabitants per km2), mainly living in rural
and sub-urban areas [8]. Currently, no precise epidemio-
logical data about TB incidence or prevalence are avail-
able for the Fimela district.
Pre-intervention diagnostic strategy
Until 2013, self-referred patients to the HCD, with pre-
sumptive symptoms of TB, according to the Senegalese
NTP guidelines, underwent acid-fast bacillus stain (AFB)
test and, if it resulted positive, HIV-screening test was
proposed and anti-TB treatment was started. If the AFB
test resulted negative, chest-X-ray in other health-care
centres was proposed (but limited to the high price of
the test and by the distance to other health-care cen-
tres). Patients’ self-referring to the HCD from the sur-
rounding villages was restricted by limited awareness of
the disease’s symptoms and by limited knowledge of
treatment’s availability at the HCD.
The StopTB project adopted at the HCD
The intervention consists of the following four main
points that were gradually introduced since 2013. First,
in order to increase awareness in the population, the TB
suggestive symptoms according to WHO (productive
cough for 10 days or more, fever, weight loss and night
sweats) were enlisted in a diagnostic brochure and dis-
tributed in all villages of the Fimela district [2]. Due to
high-illiteracy level in the area, idiomatic brochures were
suitably created by StopTB Italia Onlus.
Second, 50 women (badieu’ngox) were selected, trained,
supervised, annually retrained and paid to detect chronic
cougher in the villages surrounding Diofior and to refer the
patients to the HCD [7]. The badieu’ngox were selected
upon their knowledge of the territory, reliability among
the villagers as they are elected as social representative
of the community and for their comprehension both of
local dialects and French language. Moreover, they all
had had trained in math and French writing by previous
non-governative associations. Badieu’ngox were present be-
fore the arrival of StopTB Italia Onlus and they were already
operating in social sectors of villages’ daily life (such as first
aid, contributing to awareness of school services, exc.).
Badieu’ngox main role is being a sentinel for patients with
presumptive symptoms of TB and refer them to HCD.
Third, in February 2014, the laboratory equipment at
the HCD was enriched with one four-module Xpert
MTB/RIF system (Cepheid, Sunnydale, CA, USA),
laboratory’s technicians were trained and supervised and
retrained annually to its use and management.
Lastly, a digital chest-X-ray (CXR) mobile technology
was donated in January 2016. An Italian radiology techni-
cian was delegated to teach how to use the digital mobile
CXR and he performs annual retraining of the doctors at
the HCD.
In addition, as a result of the cooperation project, in
2017 the city hall of Diofior spontaneously donated
farmland to a selected number of patients who success-
fully completed the anti-TB treatment; the goal was to
use the possible incomes from the cultivated farmland
for the sustainment of the patients’ family and the main-
tenance of the project, in order to make it independent
from external funds.
The sequential diagnostic strategy
A sequential strategy for detection and treatment of TB
new cases was progressively adopted at the HCD (Fig. 1).
All referred presumptive TB cases, firstly underwent
AFB test, while culture test was not performed due to
structural-laboratory limitations and due to the distance
to the regional supranational laboratory (approximately
150 Km). Xpert MTB/RIF was used as a second-level
diagnostic tool for negative AFB patients with high clin-
ical suspicion of TB, according to NTP guidelines [4].
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Due to the high-cost of films, chest-X-ray was relegated as
third-level diagnostic tool for both negative AFB and Xpert
MTB/RIF patients. Before the CXR donation, all chest-X-ray
were performed in equipped centres outside the Fimela dis-
trict and paid by the patients. HIV (1/2) testing was offered
with opt-out strategy to all newly detected TB patients. All
new cases were treated with isoniazid, rifampicin, pyrazina-
mide and ethambutol (HRZE) in fixed dose combination
(FDC) (Rimstar®) for the 2 months intensive phase and with
FDC-HR (Rifinah®) for the following 4 months of continu-
ation phase; streptomycin (S) was added during the induc-
tion phase for failure and/or retreatment patients [2, 9].
All patients who started a TB treatment underwent fol-
low up visits and AFB test at one, two, five and six
months. Economic support for the patients, 20,000 Franc
of the French Community of Africa (FCFA) (the equiva-
lent of 35.8 US dollars) was offered to all patients who
completed treatment in order to stimulate retention-in
care [7]. Political commitment of the Senegalese govern-
ment has been obtained to ensure the future sustainability
of the activities after the end of the project.
Data collection and study design
Data of active pulmonary (PTB) and extra-pulmonary
tuberculosis (EPTB), from January 1st, 2012 to December
31st, 2016, were retrospectively and anonymously
registered in an electronic database. Demographic charac-
teristics (age, sex and geographical case-location) were col-
lected in addition to microbiological parameters (AFB stain
and molecular test) as well as radiological findings. More-
over, HIV status, TB retention in care and outcomes results
were recorded. Treatment outcome, favourable or unfavour-
able, was defined according to 2016 WHO definitions [2, 9].
To assess the efficacy of the cooperation project, the out-
comes of TB treatment were compared; patients were di-
vided in two subgroups, whether diagnosed in year 2012 or
thereafter. Chi square test or Fisher’s exact test were carried
out to compare categorical variables. A logistical regression
was used to compare the outcome of TB treatment before
and after the project. Variables showing a p < 0.10 were in-
cluded in a multivariable model if missing values were
below 10%. Statistical analysis was performed using the Stat-
istical Package for Social Science (SPSS version 20, IBM,
USA). Legal agreement between StopTB Italia Onlus and
the Health Care district of Diofior was settled before the be-
ginning of the project. Local ethical committee approval
was not required due the observational and retrospective
design of the study.
Results
Overall, 239 patients with TB were included, 196 (82%) of
whom after the starting of StopTB Italia Onlus activities.
Fig. 1 The sequential strategy adopted at the Health Care Centre of Diofior. TB = tuberculosis; AFB = acid-fast bacillus stain; CXR = chest-X-ray; * =
high clinical suspicion cases with negative diagnostic surveys.
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Table 1 outlines the main features of the study population
before and after the project.
Pre-intervention results
In 2012, 43 TB cases were detected. AFB at diagnosis was
positive in 35/43(81.4%) patients. Of them, the AFB score
resulted of 1+, 2+ and 3+ in 6(17.1%), 5 (14.3%) and in 24
(68.6%) cases, respectively. At 2 months follow up, 23
(65.7%) out of the 35 patients with sputum smear positive
at diagnosis had AFB stain conversion, while 4 (11.4%)
remained positive; 7 (20%) died before the 2 months fol-
low up and 1 (2.9%) was not able to expectorate. At
5 months follow up, 23 (85.2%) previously sputum smear
positive and still alive patients had AFB stain conversion,
1 (3.7%) was still positive, 3 (11.1%) were unable to expec-
torate and 1 (3.7%) patients had died before the scheduled
visit. Due to high-clinical suspicion, but negative bacterio-
logical or radiological findings, 3 patients were treated for
TB with resolutions of symptoms.
The mean treatments duration for PTB new cases was
198.2 days (range: 74–244 days SD + − 76.1 days). Three
(7%) patients were HIV-infected, but in 14 (32.5%) cases
the HIV status was unknown.
In 2012, a favourable TB treatment outcome was
reached in 29 (67.4%) cases; out of them 23 (53.4%) were
treatment completed and 6 (14%) cured. Of patients
who did not achieve a favourable TB treatment outcome,
8 (18.6%) died during the course of treatment, 3(7%) pa-
tients were lost to follow up and 3 (7%) transferred out.
Post-intervention results
A total of 196 cases were detected. According to the
WHO definitions, at the beginning of therapy, 170 (86.7%)
of them were new patients, while 10(5.1%) were
re-treatment, 6 (3.2%) were transferred from other cen-
tres, and 4 (2%) were failure. HIV-infection status was
checked in 186 (94.9%) cases at the moment of TB diag-
nosis; 10 (5.4%)patients resulted TB/HIV co-infected. All
co-infected TB/HIV patients were enrolled on antiretro-
viral therapy (ART) and counselled about the co-infection.
AFB at diagnosis was positive in 151 (77%)patients.
The AFB score resulted of 1+, 2+, 3+ in 35 (23.2%), 33
(21.8%) and 82 (54.3%) patients, respectively; quantifica-
tion of AFB stain was not available in one case. At
2 months follow up, 139 (92%) of the sputum smear
positive at diagnosis had AFB stain conversion, while 12
(8%) remained positive.
At 5 months follow up, 143(94.7%) patients had con-
trol AFB stain conversion, while 3(2%) had positive con-
trol AFB stain, 3 (2%) lacked of expectoration and
2(1.3%) were transferred out.
Following diagnosis, all but one patients started treat-
ment within 5 days. The mean treatment duration for
new PTB cases was 193.7 days (range: 150–440 days,
SD + − 28.5 days). Favourable treatment outcome was
reached in 176 patients (89.8% of the cases) after the be-
ginning of the cooperation, 34 (17.3% of the patients)
were cured and 142(72.4%) completed the treatment
course. Among TB patients who did not reach
favourable treatment outcome: 10 (5.1%) patients died
during the course of treatment, 4(2%) were transferred
out, while 3 (1.5%) were treatment failure and other 3
(1.5%) were lost to follow up.
During the collaboration, patients underwent more fre-
quently HIV screening (94% vs. 67.5%, p < 0.0001). Follow-
ing the introduction of Xpert MTB/RIF, an overall of 17
samples were Xpert MTB/RIF positive and concomitantly
AFB negative; no rpo-B mutations were detected.
The chest-X-ray led to an overall of 16 new TB diag-
noses with concomitant negative AFB stain and negative
molecular test. Out of those, six (37.5%) were made by
the mobile radiology in the year 2016. Due to
high-clinical suspicion, but negative bacteriological or
radiological findings, 15 patients were treated for TB
with resolutions of symptoms.
On the other hand, the two study periods did not dif-
fer in terms of proportion of microbiological confirmed
Table 1 Baseline characteristics of patients from 2012 to 2016 (n = 239)
Pre-intervention
n = 43(%)
Post-intervention
n = 196(%)
p
Sex, male 32 (72.1) 131 (66.8)
Mean age (±SD) 31.7 (±15.5) 41.6 (±20.0)
Performed HIV screening test at T01 29 (67.5) 186 (94.9) < 0.001
EPTB 4 (9.3) 13 (6.6) 0.37
AFB at T0 positive 35 (81.4) 151 (77)
AFB at 2-months positive 4 (11.4) 12 (8) 0.17
AFB at 5-months positive 1 (4.2) 3 (2) 0.64
Favourable outcome 29 (67.4) 176 (89.8) < 0.001
Mortality during treatment 8 (18.6%) 11 (5.6%) 0.009
EPTB extra pulmonary TB, AFB acid-fast bacillus stain, CXR chest-X-ray, T0 performed at diagnosis
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cases at diagnosis p = 0.5336 95% CI (− 6.7075 to
18.4547) and AFB negative stain at 2 months (92.1% be-
tween 2013 and 2016 vs. 65.7% in 2012 p = 0.249) and
5 months of follow up (143 patients, 97.9% between
2013 and 2016 vs. 100.0% in 2012, p = 1.0).
After the beginning of the project, TB treatment out-
come was more frequently favourable (cured and treat-
ment completed: 29 patients, 67.4% vs176 patients.
89.8%, p < 0.0001) (Fig. 2). The percentage of patients’
mortality during treatment decreased from 8 patients
(18.6%) in 2012 to 11 patients (5.6%) in the following
years (p = 0.009).
Discussion
Case detection and retention in care of TB patients are
challenging both in high and low income countries, espe-
cially in rural settings [10, 11]. Few studies reported on re-
tention in care in LIC, where up to 70% of the patients are
lost to follow up [12, 13]. This phenomenon is likely con-
tributing to the amplification of drugs resistance,
highlighting the need of new strategies for the implemen-
tation of TB retention in care and treatment [12, 14, 15].
The main finding of the present study is that the se-
quential interventions realized at HCD leaded to more
favourable treatment outcomes and lower mortality rate
compared to 2012 and compared to other LIC [16].While
the TB treatment regimen was the same throughout the
study period, cured and treatment completed rate mark-
edly improved, as confirmed by high degree of smear
negativity at the first microbiological follow up compared
to other LIC settings [17, 18]. Additionally, AFB testing
and AFB conversion rate at 2 and 5 months follow up did
not differ in reason of the study period, further supporting
improvement of retention in care.
No positive rpo-B samples were reported during the
study period, confirming the low incidence compared to
metropolitan areas as well as the low rate of treatment
failure.
Another main finding of this study is that HIV testing
was enhanced during the collaboration project, reaching
89% of TB patients and exceeding WHO estimates for
Senegal [2]. Since 2013, HIV screening was proposed to
every patient, and health care personnel received dedi-
cated training, resulting in higher acceptance rate. The
TB/HIV prevalence in the population study was con-
cordant with co-infection prevalence estimated in 2011
by the NTP in Senegal [19, 20].
CXR examination, during the period 2013–2016, pro-
vided a presumptive diagnosis of 16 cases with concomi-
tant negative AFB test and Xpert MTB/RIF, thus
confirming the importance of CXR even if burdened by
high cost (maintenance and films) in rural areas [21, 22].
In fact, while Xpert is free of charge, CXR has still to be
paid by patients at HCD.
Finally, the cooperation project resulted in socio-eco-
nomical support to all patients who completed anti-TB
treatment, possibly contributing to community con-
sciousness and decreased disease stigma [23, 24].
Study limitations
The study was limited both by no data before 2012 for a
4-year comparison and by no data about the proportion of
new cases versus previously treated in the 2012 subgroup.
Moreover, before the beginning of the study, no precise
epidemiological data were available for the Diofior area.
Furthermore, the patients of the 2012 subgroup did not
have the same diagnostic benefit and social support of the
following subgroup. Additionally, while we assessed the
overall results of the interventional cooperation project,
we did not stratify the outcomes according with the single
intervention procedures introduced.
Conclusion
A systemic project based on TB awareness among the
population, along with the implementation of diagnostic
procedures in selected health care centres and a
patient-centred approach, may favourably impacts on TB
retention in care and treatment outcomes. Social and
economic supports are fundamental pillars in the fights
against TB, both to decrease risk factors and ameliorate
patients’ conditions.
This comprehensive approach to control TB has been
feasible and effective in a Senegalese rural area and may
be exported to other similar settings.
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